Products for Research Use Only
RegisterLogin

Emfizatamab

CAT: 0804-HY-P99914-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99914-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia[1][2].
CAS Number
2559704-23-1
Product Name Alternative
GNC-038
UNSPSC
12352203
Target
CD19; CD3; PD-1/PD-L1; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/emfizatamab.html
Purity
95.495
Smiles
[Emfizatamab]
Molecular Weight
(303.229 kDa)
References & Citations
[1]Emfizatamab|[2]Wang J, et al. GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale. 2023.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Alternative Products

CatalogName
T9901A-100-01Emfizatamab
GTR18575774-01Emfizatamab Antibody
GTR18697253-01Emfizatamab Monoclonal Antibody
DHD10809Research Grade Emfizatamab
E55B1290Emfizatamab (Reference antibody)
PX-TA1893-01Emfizatamab Biosimilar - Anti-CD3e, CD19, CD274, TNFRSF9 mAb - Research Grade
A135586Emfizatamab Biosimilar (Monoclonal, (scFv-kappa-heavy) -G1_L-kappa- (scFv-heavy-kappa) - (scFv-heavy-kappa) )

Popular Products